Immuron Ltd current report, Q4 FY2017

Business Context and Reporting Period

Immuron Limited, a foreign private issuer based in Australia, filed Form 6-K on November 8, 2017. The filing serves to disseminate a public notice issued to the Australian Securities Exchange regarding the performance of its product, Travelan, for the first quarter of the fiscal year 2017 (Q1 FY2017).

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document references an attached exhibit (Exhibit 99.1) titled "Travelan Experiences Strong Q1 FY2017 Sales Growth," but the specific financial figures contained within that exhibit are not included in the provided text.

Material Changes

The Company reported strong sales growth for Travelan in Q1 FY2017 compared to the prior comparable period. No specific percentage changes or comparative figures are detailed in the filing text itself.

Guidance, Outlook, and Risks

The filing contains no explicit forward-looking guidance, management commentary beyond the sales growth announcement, or detailed discussion of risks and contingencies. The document includes a standard disclaimer stating that the report is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Verify the specific revenue figures and growth percentages for Travelan in Q1 FY2017 by reviewing the attached Exhibit 99.1.
  • Confirm the full fiscal year 2017 timeline to contextualize the Q1 results.
  • Assess whether the "strong sales growth" is driven by volume, pricing, or new market entry.
  • Review the Company's broader financial statements (Form 20-F) for overall liquidity and debt positions, as this 6-K does not provide them.